-
公开(公告)号：US11952423B2
公开(公告)日：2024-04-09
申请号：US18318610
申请日：2023-05-16
Applicant: MIE UNIVERSITY , DAIICHI SANKYO COMPANY, LIMITED
Inventor： Hiroshi Shiku , Yasushi Akahori , Kento Tanaka , Ayaka Yatsu , Junya Ichikawa , Toshiaki Ohtsuka , Shiho Kozuma , Ryuji Hashimoto , Makiko Nakayama , Naoya Shinozaki , Kensuke Nakamura , Ichiro Watanabe , Shinji Furuzono
CPC classification number: C07K16/2809 , C07K16/32 , C07K2317/31 , C07K2317/52 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/528 , C07K2317/53 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622
Abstract: A novel antibody that can be used as an anti-tumor agent and an anti-tumor agent that comprises, as an active ingredient, a molecule containing such an antibody.
-
公开(公告)号：US20230212306A1
公开(公告)日：2023-07-06
申请号：US18146817
申请日：2022-12-27
Applicant: Daiichi Sankyo Company, Limited , The University of Tokyo
Inventor： Kensuke Miyake , Yusuke Murakami , Yuji Motoi , Atsuo Kanno , Toshiyuki Shimizu , Umeharu Ohto , Takaichi Shimozato , Atsushi Manno , Takashi Kagari , Jun Ishiguro , Kensuke Nakamura , Takashi Isobe
IPC: C07K16/28 , A61K39/395 , A61K45/06
CPC classification number: C07K16/2896 , A61K39/3955 , A61K45/06 , C07K2317/76 , C07K2317/24 , A61K2039/505
Abstract: The present invention provides a pharmaceutical composition comprising an antibody which binds specifically to human TLR7 or monkey TLR7 and does not bind to mouse TLR7 or rat TLR7, and has an activity of inhibiting a function of human TLR7 or monkey TLR7, and the like.
-
公开(公告)号：US11091560B2
公开(公告)日：2021-08-17
申请号：US17069760
申请日：2020-10-13
Applicant: Daiichi Sankyo Company, Limited , The University of Tokyo
Inventor： Kensuke Miyake , Yusuke Murakami , Yuji Motoi , Atsuo Kanno , Toshiyuki Shimizu , Umeharu Ohto , Takaichi Shimozato , Atsushi Manno , Takashi Kagari , Jun Ishiguro , Kensuke Nakamura , Takashi Isobe
IPC: C07K16/28 , A61K39/395
Abstract: The present invention provides a pharmaceutical composition comprising an antibody which binds specifically to human TLR7 or monkey TLR7 and does not bind to mouse TLR7 or rat TLR7, and has an activity of inhibiting a function of human TLR7 or monkey TLR7, and the like.
-
公开(公告)号：US20210040225A1
公开(公告)日：2021-02-11
申请号：US17069760
申请日：2020-10-13
Applicant: Daiichi Sankyo Company, Limited , The University of Tokyo
Inventor： Kensuke Miyake , Yusuke Murakami , Yuji Motoi , Atsuo Kanno , Toshiyuki Shimizu , Umeharu Ohto , Takaichi Shimozato , Atsushi Manno , Takashi Kagari , Jun Ishiguro , Kensuke Nakamura , Takashi Isobe
IPC: C07K16/28
Abstract: The present invention provides a pharmaceutical composition comprising an antibody which binds specifically to human TLR7 or monkey TLR7 and does not bind to mouse TLR7 or rat TLR7, and has an activity of inhibiting a function of human TLR7 or monkey TLR7, and the like.
-
公开(公告)号：US12233155B2
公开(公告)日：2025-02-25
申请号：US17874239
申请日：2022-07-26
Applicant: DAIICHI SANKYO COMPANY, LIMITED
Inventor： Atsuko Saito , Tsuyoshi Hirata , Kensuke Nakamura
IPC: A61K47/68 , A61K9/00 , A61K31/4745 , A61P35/00 , C07K16/28
Abstract: It is an object of the present invention to provide an antibody binding to CDH6 and having internalization activity, an antibody-drug conjugate of the antibody and a drug having antitumor activity, a pharmaceutical product comprising the antibody-drug conjugate and having therapeutic effects on a tumor, a method for treating a tumor using the antibody, the antibody-drug conjugate or the pharmaceutical product, and the like. The present invention provides an anti-CDH6 antibody having internalization activity, an antibody-drug conjugate of the antibody and a drug having antitumor activity, a pharmaceutical product comprising the antibody or the antibody-drug conjugate, and a method for treating a tumor.
-
Patent Agency Ranking
公开(公告)号：US12024566B2
公开(公告)日：2024-07-02
申请号：US17258115
申请日：2019-07-09
Inventor： Takashi Matozaki , Mayumi Sue , Kensuke Nakamura , Chigusa Yoshimura
IPC: A61K39/395 , A61P35/00 , C07K16/28 , C07K16/32 , A61K39/00
CPC classification number: C07K16/2896 , A61K2039/505 , A61P35/00 , C07K16/2863 , C07K16/2887 , C07K16/32 , C07K2317/21 , C07K2317/565 , C07K2317/72 , C07K2317/732 , C07K2317/76
Abstract: An anti-SIRPα antibody that can be used as a tumor agent and an anti-tumor agent comprising the antibody as an active ingredient. An antibody that binds specifically to human SIRPα to inhibit binding of human SIRPα to CD47.
-
公开(公告)号：US11618785B2
公开(公告)日：2023-04-04
申请号：US16472346
申请日：2017-12-21
Applicant: Daiichi Sankyo Company, Limited
Inventor： Tohru Takahashi , Chigusa Yoshimura , Shiho Kozuma , Kensuke Nakamura , Chikako Suzuki , Junya Ichikawa
Abstract: The present invention provides a novel antibody binding to human CD3, and a molecule having antigen binding activity that includes the antibody.
The present invention provides a novel antibody binding to human CD3, a molecule having antigen binding activity that includes the antibody, and a pharmaceutical composition having cytotoxic activity that includes the antibody or the molecule as an active ingredient.-
公开(公告)号：US11446386B2
公开(公告)日：2022-09-20
申请号：US16613203
申请日：2018-05-14
Applicant: DAIICHI SANKYO COMPANY, LIMITED
Inventor： Atsuko Saito , Tsuyoshi Hirata , Kensuke Nakamura
IPC: A61K47/68 , C07K16/28 , A61P35/00 , A61K31/4745
Abstract: It is an object of the present invention to provide an antibody binding to CDH6 and having internalization activity, an antibody-drug conjugate of the antibody and a drug having antitumor activity, a pharmaceutical product comprising the antibody-drug conjugate and having therapeutic effects on a tumor, a method for treating a tumor using the antibody, the antibody-drug conjugate or the pharmaceutical product, and the like. The present invention provides an anti-CDH6 antibody having internalization activity, an antibody-drug conjugate of the antibody and a drug having antitumor activity, a pharmaceutical product comprising the antibody or the antibody-drug conjugate, and a method for treating a tumor.
-
公开(公告)号：US20210332149A1
公开(公告)日：2021-10-28
申请号：US17366820
申请日：2021-07-02
Applicant: Daiichi Sankyo Company, Limited , The University of Tokyo
Inventor： Kensuke Miyake , Yusuke Murakami , Yuji Motoi , Atsuo Kanno , Toshiyuki Shimizu , Umeharu Ohto , Takaichi Shimozato , Atsushi Manno , Takashi Kagari , Jun Ishiguro , Kensuke Nakamura , Takashi Isobe
IPC: C07K16/28
Abstract: The present invention provides a pharmaceutical composition comprising an antibody which binds specifically to human TLR7 or monkey TLR7 and does not bind to mouse TLR7 or rat TLR7, and has an activity of inhibiting a function of human TLR7 or monkey TLR7, and the like.
-
公开(公告)号：US20190202911A1
公开(公告)日：2019-07-04
申请号：US16331171
申请日：2017-09-07
Applicant: Daiichi Sankyo Company, Limited
Inventor： Ryuta Mukasa , Kensuke Nakamura , Sumie Muramatsu , Naoyuki Makita
CPC classification number: C07K16/2803 , A61K31/56 , A61K39/395 , A61K45/00 , A61K2039/505 , A61P1/04 , A61P3/10 , A61P5/16 , A61P7/04 , A61P7/06 , A61P17/00 , A61P17/06 , A61P19/02 , A61P21/00 , A61P21/04 , A61P25/00 , A61P27/02 , A61P29/00 , A61P31/00 , A61P35/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P43/00 , C07K16/28 , C07K16/46 , C07K2317/24 , C07K2317/41 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C12N5/10 , C12N15/09
Abstract: To provide a novel antibody. Provided is a monoclonal antibody or a binding fragment thereof that binds to domain 3 of human LAG-3 and has one or more of the properties described in (ii) to (v), and the properties described in (i) and (vi) below: (i) having in vitro ADCC activity; (ii) reducing the number of LAG-3 positive cells in vivo in low fucose form; (iii) suppressing experimental autoimmune encephalomyelitis in vivo in low fucose form; (iv) binding to human activated T cells; (v) human LAG-3 binds to human major histocompatibility complex class II molecules in the presence of the antibody or the binding fragment thereof; and (vi) the presence of the antibody or the binding fragment thereof allowing human LAG-3 to exert a human T cell suppression function.
-
-
-
-
-
-
-
-
-
Search Results
27
records
(took 0.02 seconds)
